Welcome to LookChem.com Sign In|Join Free

CAS

  • or

137102-65-9

Post Buying Request

137102-65-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

137102-65-9 Usage

General Description

[(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is a chemical compound with the molecular formula C12H19N3O2. It is the ester form of [(1R)-2-amino-1-phenylethyl]-carbamic acid, a compound that has potential therapeutic applications for the treatment of neurological disorders. This chemical is used as a reagent in chemical reactions to form new compounds with potential pharmaceutical or industrial uses. Its properties and applications make it a valuable tool in chemical research and development, as well as in the pharmaceutical industry for the potential treatment of various medical conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 137102-65-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,1,0 and 2 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 137102-65:
(8*1)+(7*3)+(6*7)+(5*1)+(4*0)+(3*2)+(2*6)+(1*5)=99
99 % 10 = 9
So 137102-65-9 is a valid CAS Registry Number.

137102-65-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-[(1R)-2-amino-1-phenylethyl]carbamate

1.2 Other means of identification

Product number -
Other names tert-butyl (R)-2-amino-1-phenylethylcarbamate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:137102-65-9 SDS

137102-65-9Relevant articles and documents

Preparation method of key intermediate of elagolix

-

Paragraph 0016; 0022; 0028; 0034; 0040; 0046, (2019/07/16)

The invention relates to the field of pharmacy, and concretely relates to a preparation method of a key intermediate of elagolix. The method adopts simple and easily available Boc-D-phenylglycinol asa starting material, and comprises the following steps:

SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS

-

Paragraph 0067; 0068, (2017/03/21)

Synthesis methods to produce a series of carboxamides built off of an (S)-2-amino acid backbone or an (R)-2-amino acid backbone, depending upon the desired diastereomer of the end product.

Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: Potent inhibitors of R5 HIV-1 replication

Skerlj, Renato,Bridger, Gary,Zhou, Yuanxi,Bourque, Elyse,McEachern, Ernest,Metz, Markus,Harwig, Curtis,Li, Tong-Shuang,Yang, Wen,Bogucki, David,Zhu, Yongbao,Langille, Jonathan,Veale, Duane,Ba, Tuya,Bey, Michael,Baird, Ian,Kaller, Alan,Krumpak, Maria,Leitch, David,Satori, Michael,Vocadlo, Krystyna,Guay, Danielle,Nan, Susan,Yee, Helen,Crawford, Jason,Chen, Gang,Wilson, Trevor,Carpenter, Bryon,Gauthier, David,MacFarland, Ron,Mosi, Renee,Bodart, Veronique,Wong, Rebecca,Fricker, Simon,Schols, Dominique

, p. 8049 - 8065 (2013/11/06)

The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure-activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (R5) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 137102-65-9